drugset / Trial / NCT00192296
Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Phase I study to evaluate the safety and tolerability of escalating single IV doses of MEDI-528.
Timeline
- Start
- 2004-08
- Primary completion
- 2005-02
- Completion
- 2005-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ENOKIZUMAB | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | ENOKIZUMAB | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | ENOKIZUMAB | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | ENOKIZUMAB | Monoclonal antibody | 9 mg/kg | Intravenous |